As paricalcitol is a vitamin D receptor agonist that diffuses through the blood-brain barrier and shows relatively few side effects such as hypercalcemia and hyperphosphatemia, it may be a more appropriate neuroprotective drug than vitamin D itself for clinical applications [30, 31]. This evidence concerns the gene VDR and Hypercalcemia.